| Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification J Haldrup, S Andersen, ARLV Labial, JH Wolff, FP Frandsen, TW Skov, ... Nucleic Acids Research 51 (18), 10059-10074, 2023 | 21 | 2023 |
| Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma EA Thomsen, AB Rovsing, MV Anderson, H Due, J Huang, Y Luo, ... Molecular Oncology 14 (9), 1978-1997, 2020 | 19 | 2020 |
| Resistance to vincristine in DLBCL by disruption of p53‐induced cell cycle arrest and apoptosis mediated by KIF18B and USP28 AB Rovsing, EA Thomsen, I Nielsen, TW Skov, Y Luo, K Dybkær, ... British Journal of Haematology 202 (4), 825-839, 2023 | 10 | 2023 |
| Restriction of C1-inhibitor activity in hereditary angioedema by dominant-negative effects of disease-associated SERPING1 gene variants LB Ryø, D Haslund, AB Rovsing, R Pihl, W Sanrattana, S de Maat, ... Journal of Allergy and Clinical Immunology 152 (5), 1218-1236. e9, 2023 | 4 | 2023 |
| Cell-targeted gene modification by delivery of CRISPR-Cas9 ribonucleoprotein complexes in pseudotyped lentivirus-derived nanoparticles IH Nielsen, AB Rovsing, JH Janns, EA Thomsen, A Ruzo, A Bøggild, ... Molecular Therapy Nucleic Acids 35 (4), 2024 | 3 | 2024 |
| Multiparametric optimization of human primary B-cell cultures using Design of Experiments AB Rovsing, K Green, L Jensen, IH Nielsen, JG Mikkelsen, SE Degn bioRxiv, 2025.01. 16.633474, 2025 | | 2025 |
| Genome-Scale CRISPRa and CRISPRi screening for lncRNA drivers of prostate cancer progression S Weiss, A Lord, B Schmierer, AB Rovsing, EA Thomsen, JG Mikkelsen, ... Cancer Research 83 (7_Supplement), 3778-3778, 2023 | | 2023 |
